Plasma Surgical

Plasma Surgical

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Plasma Surgical is a private medical device innovator specializing in pure-plasma energy technology for surgery. Its flagship product, the PlasmaJet Ultra+, is an all-in-one surgical instrument designed for precision tissue management with minimal thermal spread, targeting complex soft tissue procedures. The company is commercial in Europe, Australia, and New Zealand, with a primary focus on gynecological oncology and endometriosis, aiming to enable more conservative, minimally invasive surgeries and improve patient outcomes.

EndometriosisOvarian CancerGeneral Soft Tissue Surgery

Technology Platform

Pure-Plasma energy technology generating a controlled, rapidly dissipating stream of ionized gas for precise surgical cutting, dissection, vaporization, coagulation, and surface sealing of soft tissue with minimal lateral thermal damage.

Opportunities

Significant opportunity in the growing markets for minimally invasive endometriosis surgery and optimal cytoreduction in ovarian cancer, where precision tissue preservation is critical.
The versatile platform also has potential for expansion into other surgical specialties requiring fine dissection and ablation.

Risk Factors

Facing intense competition from large, established medical device companies with broader portfolios and sales reach.
Requires continuous generation of high-level clinical evidence and cost-benefit data to drive adoption and justify the technology's value to cost-conscious hospital systems.

Competitive Landscape

Competes in the surgical energy device market against major players like Medtronic (electrosurgery), Johnson & Johnson (Ethicon), and Olympus, who offer ultrasonic (e.g., Harmonic), advanced bipolar, and laser devices. PlasmaJet's differentiation is its pure-plasma technology, which claims superior precision and minimal thermal spread compared to these alternatives.